<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463567</url>
  </required_header>
  <id_info>
    <org_study_id>CQAB149B2335S</org_study_id>
    <nct_id>NCT00463567</nct_id>
  </id_info>
  <brief_title>26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A 26-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 &amp; 600 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 µg b.i.d.) and Open Label Tiotropium (18 µg o.d.) as Active Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of
      indacaterol (75, 150, 300 &amp; 600 µg o.d.) in order to select two doses to carry forward into
      study Stage 2. Study Stage 2 will provide pivotal confirmation of efficacy, safety, and
      tolerability of the selected indacaterol doses in patients with COPD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 12 Weeks of Treatment</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
    <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of &quot;Days of Poor Control&quot; Reported Over the 26 Week Treatment Period</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>A Chronic Obstructive Pulmonary Disease (COPD) &quot;day of poor control&quot; was defined as any day in the participant's diary with a score ≥2 (moderate or severe) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness). Score for each symptom ranges from 0-3; a higher number indicates a more severe symptom. The model contained baseline percentage of &quot;days of poor control&quot; as well as FEV1 reversibility components as covariates.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">2059</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>COPD</condition>
  <condition>Lung Diseases, Obstructive</condition>
  <arm_group>
    <arm_group_label>Indacaterol 150 µg (Continued Into Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indacaterol 300 µg (Continued Into Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium 18 µg (Continued Into Stage 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Continued Into Stage 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indacaterol 75 µg (Not Continued into Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indacaterol 600 µg (Not Continued Into Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol 12 µg (Not Continued Into Stage 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol</intervention_name>
    <description>In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).</description>
    <arm_group_label>Indacaterol 150 µg (Continued Into Stage 2)</arm_group_label>
    <arm_group_label>Indacaterol 300 µg (Continued Into Stage 2)</arm_group_label>
    <arm_group_label>Indacaterol 75 µg (Not Continued into Stage 2)</arm_group_label>
    <arm_group_label>Indacaterol 600 µg (Not Continued Into Stage 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol (12 µg b.i.d.)</intervention_name>
    <description>Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.</description>
    <arm_group_label>Formoterol 12 µg (Not Continued Into Stage 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium (18 µg o.d.)</intervention_name>
    <description>Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.</description>
    <arm_group_label>Tiotropium 18 µg (Continued Into Stage 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Indacaterol</intervention_name>
    <description>In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).</description>
    <arm_group_label>Indacaterol 150 µg (Continued Into Stage 2)</arm_group_label>
    <arm_group_label>Indacaterol 300 µg (Continued Into Stage 2)</arm_group_label>
    <arm_group_label>Placebo (Continued Into Stage 2)</arm_group_label>
    <arm_group_label>Indacaterol 75 µg (Not Continued into Stage 2)</arm_group_label>
    <arm_group_label>Formoterol 12 µg (Not Continued Into Stage 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Formoterol</intervention_name>
    <description>In the morning and in the evening, placebo to formoterol delivered via Aerolizer.</description>
    <arm_group_label>Indacaterol 150 µg (Continued Into Stage 2)</arm_group_label>
    <arm_group_label>Indacaterol 300 µg (Continued Into Stage 2)</arm_group_label>
    <arm_group_label>Placebo (Continued Into Stage 2)</arm_group_label>
    <arm_group_label>Indacaterol 75 µg (Not Continued into Stage 2)</arm_group_label>
    <arm_group_label>Indacaterol 600 µg (Not Continued Into Stage 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior
             to initiation of any study-related procedure

          -  Co-operative outpatients with a diagnosis of COPD (moderate to severe as classified by
             the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) Guidelines,
             2005) and:

               -  Smoking history of at least 20 pack years

               -  Post-bronchodilator FEV1 &lt; 80% and ≥ 30% of the predicted normal value.

               -  Post-bronchodilator FEV1/FVC &lt; 70% (Post refers to within 30 min of inhalation of
                  400 µg of salbutamol)

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to
             Visit 1 or during the run-in period

          -  Patients requiring long term oxygen therapy (&gt; 15 h a day)

          -  Patients who have had a respiratory tract infection 6 weeks prior to V1 (with further
             criteria)

          -  Patients with concomitant pulmonary disease, pulmonary tuberculosis, or clinically
             significant bronchiectasis

          -  Patients with a history of asthma (with further criteria)

          -  Patients with Type I or uncontrolled Type II diabetes

          -  Patients with contraindications for tiotropium

          -  Patients who have clinically relevant laboratory abnormalities or a clinically
             significant abnormality

          -  Any patient with active cancer or a history of cancer with less than 5 years disease
             free survival time

          -  Patients with a history of long QT syndrome or whose QTc interval is prolonged

          -  Patients with a hypersensitivity to any of the study drugs or drugs with similar
             chemical structures

          -  Patients who have had treatment with the investigational drug (with further criteria)

          -  Patients who have had live attenuated vaccinations within 30 days prior to visit 1, or
             during run-in period

          -  Patients with known history of non compliance to medication

          -  Patients unable to satisfactorily use a dry powder inhaler device or perform
             spirometry measurements

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Medicine Associates PC</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasper Summit Research</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associate of Mobile, PC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates, PA</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates, PA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists, LTD</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Pharmaceutical Research, LLC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canyon Clinical Research, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAVAHSC / Pulmonary Section</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Pine Bluff</city>
        <state>Arkansas</state>
        <zip>71603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Rancho Amigos Medical Center</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research - North Coast</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Specialists Medical Group and research Center</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interlink Research Institute</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Research Foundation, Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Institute for Respiratory Diseases</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Clinical Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92869</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Allergy &amp; Asthma Medical Group</name>
      <address>
        <city>Palmdale</city>
        <state>California</state>
        <zip>93551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intergrated Research Group</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates of Santa Clara Res. Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Los Angeles Healthcare System</name>
      <address>
        <city>Sepulveda</city>
        <state>California</state>
        <zip>91343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bensch Clinical Research Associates</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Pulmonary Medical Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Clinical Research Inc</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulder Medical Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical &amp; Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Colorado Pulmonary Consultants, PC</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New West Physicians Clinical research</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Center for Clinical Research</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western States Clinical Research</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung Health &amp; Sleep Enhancement Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610 - 0277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Jacksonville Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emerald Coast Clinical Research, LLC</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pensacola Research Consultants</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrity Research</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brevard Pulmonary Specialists</name>
      <address>
        <city>Rockledge</city>
        <state>Florida</state>
        <zip>32955</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma &amp; Allergy Research Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Miami Clinical Research, LLC</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Medical Group, PA</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clireco, Inc</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neutrotrials Research Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Clinical Research</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Pulmonary Medicine</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze &amp; Itch Associates, LLC</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois Clinical Research Center</name>
      <address>
        <city>O'Fallon</city>
        <state>Illinois</state>
        <zip>62269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital Anderson</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bend Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Clinical Research Corporation</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart of America Research Institute</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Crescent Springs</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Medical research Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Asthma and Allergy Research Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Research, LLC</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rx R&amp;D</name>
      <address>
        <city>Metaire</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Sciences Center/LSU School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore Research Associates</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma, Immunology, Pharmaceutical Studies</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primecare Physician Associates</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <zip>04005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Asthma and Allergy Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miray Medical Center</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fallon Clinic at Worcester Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSite, Inc</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital; Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Respiratory Institute of Southwest Michigan</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Medical Education Alliance</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48602 - 5303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cardio-Pulmonary Research</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City University of Medicine and Biosciences</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64106 - 1453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri KC/ Truman Medical</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108-2677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Centre</name>
      <address>
        <city>St, Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Chest Consultants</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U School of Medicine, Center for Clinical Studies</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Health Research Institute</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somnos Laboratories, Inc</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omaha VA Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Allergy and Asthma Clinic</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Centre for Allergy, Asthma &amp; Immunology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creigton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Clinical Research, Inc</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center - Pulmonary Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198 - 5885</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Asthma &amp; Allergy Center, PC</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of NV</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Clinical Research</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Critical Care Associates, PA</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>7101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Allergy Associates, PA</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Critical Care Services</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent Medical Associates</name>
      <address>
        <city>Astoria</city>
        <state>New York</state>
        <zip>11102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates</name>
      <address>
        <city>Cortland</city>
        <state>New York</state>
        <zip>13045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nassau Chest Physicians, PC</name>
      <address>
        <city>Massapequa</city>
        <state>New York</state>
        <zip>11758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Pulmonary Associates, PC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAIR research Centre</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sensenbrenner Primary Care</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cloverdale Research Facility</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merit Care Medical Group</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizons Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Centre</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109-1998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University - Davis Heart and Lung Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington-Davis Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Winder Associates</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Health Care Specialists</name>
      <address>
        <city>Thornville</city>
        <state>Ohio</state>
        <zip>43076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacotherapy Research Associates, Inc</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Allergy and Asthma Clinic</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynne Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultants, Inc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>River Road Medical Group</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon, PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Clinical Research Associates</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227-1110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-State Medical Group</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009 - 1957</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chest Diseases of Northwestern PA</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Allergy &amp;Pulmonary Associates, PC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pittsburgh Pulmonary Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Hills Pulmonary Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Center for Clinical Research</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners in Clinical Research</name>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <zip>02864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low County Lung and Critical Care, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406-7108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hugh D. Durrence, MD, Family Medicine</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Plus South - Strand Family Practice</name>
      <address>
        <city>Garden City</city>
        <state>South Carolina</state>
        <zip>29576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Pharmaceutical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Pulmonary Medicine, PA - Sleep Disorders Lab</name>
      <address>
        <city>Varnville</city>
        <state>South Carolina</state>
        <zip>29944</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiSpeciality Clinical Research</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dickson Family Medicine Group, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208-3599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Medical, P.C</name>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <zip>37825-1409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaTex Research LLC</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Clinic - Corsicana</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research &amp; Consulting, Inc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231-4307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma &amp; Allergy Research Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Sky Medical Research</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Pulmonary &amp; Critical Care</name>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555 - 0561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>*Private Practice*</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houstons Veteran's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Allergy and Asthma, PA</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Assurance Research Centre</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Audie L. Murphy VA Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229 - 4404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Research Center, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmed Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Lung Center</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnston Memorial Hospital Pulmonary Research</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynchburg Pulmonary Associates</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madrona Medical Group - Clinical Research Dept.</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Research Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William L. Gray Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Consultants, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army medical Center / Dept. of Army</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Area Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>26304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ajax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Chatham</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Gatineau</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Moncton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Niagara Falls</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Saskatoon</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>St John's</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>St John</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>St Romuald</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ste-Foy</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Trois-Rivieres</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Waterloo</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Windsor</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Winnipeg</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bruhl</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Dachau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Fuerth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hoyerswerda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kaufbeuren</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Landsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Oranienburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Oschersleben</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ratingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Steinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Banglore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Caranazalem</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hyderabaad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kolkatta</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ludhiana</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Busto Arsizio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Chioggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Crema</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ponce</city>
        <zip>716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Calde Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Galdakano</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Gerona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Orense</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ponferrada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Puerto de Sagunto</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Vic</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Vila-Real</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Jonkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Lidingo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Lulea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>LinKou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Anakara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Yenisehir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2007</study_first_submitted>
  <study_first_submitted_qc>April 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <results_first_submitted>July 22, 2011</results_first_submitted>
  <results_first_submitted_qc>July 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2011</results_first_posted>
  <last_update_submitted>July 22, 2011</last_update_submitted>
  <last_update_submitted_qc>July 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>external affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>indacaterol</keyword>
  <keyword>long acting beta-2 agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study consisted of two stages: a dose selection stage (Stage 1, 2 weeks) from which 2 out of 4 Indacaterol doses were selected following interim analysis to continue into Stage 2 for comparisons of efficacy, safety, and tolerability for total treatment of up to 26 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Indacaterol 150 µg (Continued Into Stage 2)</title>
          <description>In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="P2">
          <title>Indacaterol 300 µg (Continued Into Stage 2)</title>
          <description>In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="P3">
          <title>Tiotropium (Continued Into Stage 2)</title>
          <description>Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="P4">
          <title>Placebo (Continued Into Stage 2)</title>
          <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="P5">
          <title>Indacaterol 75 µg (Not Continued Into Stage 2)</title>
          <description>In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="P6">
          <title>Indacaterol 600 µg (Not Continued Into Stage 2)</title>
          <description>In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="P7">
          <title>Formoterol 12 µg (Not Continued Into Stage 2)</title>
          <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="420">Randomized Participants</participants>
                <participants group_id="P2" count="418"/>
                <participants group_id="P3" count="420"/>
                <participants group_id="P4" count="425"/>
                <participants group_id="P5" count="130"/>
                <participants group_id="P6" count="123"/>
                <participants group_id="P7" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population: Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="416"/>
                <participants group_id="P2" count="416"/>
                <participants group_id="P3" count="415"/>
                <participants group_id="P4" count="418"/>
                <participants group_id="P5" count="127">'Completed' indicates the number of patients in the interim analysis.</participants>
                <participants group_id="P6" count="122">'Completed' indicates the number of patients in the interim analysis.</participants>
                <participants group_id="P7" count="122">'Completed' indicates the number of patients in the interim analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
                <participants group_id="P2" count="341"/>
                <participants group_id="P3" count="331"/>
                <participants group_id="P4" count="294"/>
                <participants group_id="P5" count="107"/>
                <participants group_id="P6" count="102"/>
                <participants group_id="P7" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="89"/>
                <participants group_id="P4" count="131"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal lab value(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Indacaterol 150 µg (Continued Into Stage 2)</title>
          <description>In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="B2">
          <title>Indacaterol 300 µg (Continued Into Stage 2)</title>
          <description>In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="B3">
          <title>Tiotropium 18 µg (Continued Into Stage 2)</title>
          <description>Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="B4">
          <title>Placebo (Continued Into Stage 2)</title>
          <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="B5">
          <title>Indacaterol 75 µg (Not Continued Into Stage 2)</title>
          <description>In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="B6">
          <title>Indacaterol 600 µg (Not Continued Into Stage 2)</title>
          <description>In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="B7">
          <title>Formoterol 12 µg (Not Continued Into Stage 2)</title>
          <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="416"/>
            <count group_id="B2" value="416"/>
            <count group_id="B3" value="415"/>
            <count group_id="B4" value="418"/>
            <count group_id="B5" value="127"/>
            <count group_id="B6" value="122"/>
            <count group_id="B7" value="122"/>
            <count group_id="B8" value="2036"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Baseline Measures were based on the Safety Population that included all participants who received at least one dose of study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 40 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="215"/>
                    <measurement group_id="B4" value="215"/>
                    <measurement group_id="B5" value="58"/>
                    <measurement group_id="B6" value="60"/>
                    <measurement group_id="B7" value="56"/>
                    <measurement group_id="B8" value="1048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="203"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="62"/>
                    <measurement group_id="B7" value="66"/>
                    <measurement group_id="B8" value="988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="163"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="269"/>
                    <measurement group_id="B4" value="255"/>
                    <measurement group_id="B5" value="76"/>
                    <measurement group_id="B6" value="74"/>
                    <measurement group_id="B7" value="70"/>
                    <measurement group_id="B8" value="1266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 12 Weeks of Treatment</title>
        <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.</description>
        <time_frame>after 12 weeks of treatment</time_frame>
        <population>Participants from the Intent to Treat Population of Stage 2 of the study who received at least one dose of study drug and for whom data was available for FEV1 at 12 weeks. Imputed with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 150 µg (Continued Into Stage 2)</title>
            <description>In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 300 µg (Continued Into Stage 2)</title>
            <description>In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 µg (Continued Into Stage 2)</title>
            <description>Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Continued Into Stage 2)</title>
            <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 12 Weeks of Treatment</title>
          <description>FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.</description>
          <population>Participants from the Intent to Treat Population of Stage 2 of the study who received at least one dose of study drug and for whom data was available for FEV1 at 12 weeks. Imputed with last observation carried forward.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="393"/>
                <count group_id="O4" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.015"/>
                    <measurement group_id="O2" value="1.46" spread="0.015"/>
                    <measurement group_id="O3" value="1.42" spread="0.015"/>
                    <measurement group_id="O4" value="1.28" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of &quot;Days of Poor Control&quot; Reported Over the 26 Week Treatment Period</title>
        <description>A Chronic Obstructive Pulmonary Disease (COPD) &quot;day of poor control&quot; was defined as any day in the participant's diary with a score ≥2 (moderate or severe) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness). Score for each symptom ranges from 0-3; a higher number indicates a more severe symptom. The model contained baseline percentage of “days of poor control” as well as FEV1 reversibility components as covariates.</description>
        <time_frame>up to 26 weeks</time_frame>
        <population>Intent to Treat population consisting of all participants in Stage 2 of the study who received at least one dose of study drug. Eligible participants for the analysis were those with ≥7 evaluable diary days in the baseline period and ≥30% evaluable diary days (at least 20 days) in total.</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 150 µg (Continued Into Stage 2)</title>
            <description>In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 300 µg (Continued Into Stage 2)</title>
            <description>In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (Continued Into Stage 2)</title>
            <description>Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Continued Into Stage 2)</title>
            <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of &quot;Days of Poor Control&quot; Reported Over the 26 Week Treatment Period</title>
          <description>A Chronic Obstructive Pulmonary Disease (COPD) &quot;day of poor control&quot; was defined as any day in the participant's diary with a score ≥2 (moderate or severe) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness). Score for each symptom ranges from 0-3; a higher number indicates a more severe symptom. The model contained baseline percentage of “days of poor control” as well as FEV1 reversibility components as covariates.</description>
          <population>Intent to Treat population consisting of all participants in Stage 2 of the study who received at least one dose of study drug. Eligible participants for the analysis were those with ≥7 evaluable diary days in the baseline period and ≥30% evaluable diary days (at least 20 days) in total.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
                <count group_id="O2" value="384"/>
                <count group_id="O3" value="391"/>
                <count group_id="O4" value="362"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="1.51"/>
                    <measurement group_id="O2" value="30.8" spread="1.51"/>
                    <measurement group_id="O3" value="31.0" spread="1.50"/>
                    <measurement group_id="O4" value="34.0" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 2 Weeks of Treatment</title>
        <description>Interim Analysis: Stage 1.
Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.</description>
        <time_frame>Day 15, After 2 Weeks of treatment in Stage 1</time_frame>
        <population>Interim Intent-to-treat (ITT) population included participants in Stage 1 of the study who received at least one dose of study drug and for whom data were available for Trough FEV1 at Day 15. Missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 150 µg</title>
            <description>In the morning, Indacaterol 150 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 300 µg</title>
            <description>In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 µg</title>
            <description>Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®).
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O5">
            <title>Indacaterol 75 µg</title>
            <description>In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 600 µg</title>
            <description>In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O7">
            <title>Formoterol 12 µg</title>
            <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 2 Weeks of Treatment</title>
          <description>Interim Analysis: Stage 1.
Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.</description>
          <population>Interim Intent-to-treat (ITT) population included participants in Stage 1 of the study who received at least one dose of study drug and for whom data were available for Trough FEV1 at Day 15. Missing data were imputed using last observation carried forward (LOCF).</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="112"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="104"/>
                <count group_id="O6" value="108"/>
                <count group_id="O7" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.024"/>
                    <measurement group_id="O2" value="1.52" spread="0.024"/>
                    <measurement group_id="O3" value="1.45" spread="0.023"/>
                    <measurement group_id="O4" value="1.31" spread="0.024"/>
                    <measurement group_id="O5" value="1.46" spread="0.024"/>
                    <measurement group_id="O6" value="1.51" spread="0.024"/>
                    <measurement group_id="O7" value="1.42" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 1 Hour to 4 Hour Post Morning Dose After 2 Weeks of Treatment</title>
        <description>Interim Analysis: Stage 1.
Spirometry was conducted according to internationally accepted standards. Standardized with respect to time (AUC 1h-4h) for FEV1 measurements taken from 1 hour to 4 hour post morning dose on Day 14. Standardized FEV1 AUC was calculated by the trapezoidal rule. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.</description>
        <time_frame>Day 14, After 2 Weeks of treatment in Stage 1</time_frame>
        <population>Interim Intent-to-treat (ITT) population included participants in Stage 1 of the study who received at least one dose of study drug and for whom data were available for AUC 1h-4h FEV1 at Day 14. Missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Indacaterol 150 µg</title>
            <description>In the morning, Indacaterol 150 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O2">
            <title>Indacaterol 300 µg</title>
            <description>In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 18 µg</title>
            <description>Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®).
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O5">
            <title>Indacaterol 75 µg</title>
            <description>In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O6">
            <title>Indacaterol 600 µg</title>
            <description>In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
          <group group_id="O7">
            <title>Formoterol 12 µg</title>
            <description>In the morning, Placebo to Indacaterol delivered via SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 1 Hour to 4 Hour Post Morning Dose After 2 Weeks of Treatment</title>
          <description>Interim Analysis: Stage 1.
Spirometry was conducted according to internationally accepted standards. Standardized with respect to time (AUC 1h-4h) for FEV1 measurements taken from 1 hour to 4 hour post morning dose on Day 14. Standardized FEV1 AUC was calculated by the trapezoidal rule. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.</description>
          <population>Interim Intent-to-treat (ITT) population included participants in Stage 1 of the study who received at least one dose of study drug and for whom data were available for AUC 1h-4h FEV1 at Day 14. Missing data were imputed using last observation carried forward (LOCF).</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="97"/>
                <count group_id="O7" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.034"/>
                    <measurement group_id="O2" value="1.58" spread="0.034"/>
                    <measurement group_id="O3" value="1.49" spread="0.034"/>
                    <measurement group_id="O4" value="1.30" spread="0.033"/>
                    <measurement group_id="O5" value="1.50" spread="0.034"/>
                    <measurement group_id="O6" value="1.53" spread="0.034"/>
                    <measurement group_id="O7" value="1.52" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Population including all participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Indacaterol 150 µg (Continued Into Stage 2)</title>
          <description>In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="E2">
          <title>Indacaterol 300 µg (Continued Into Stage 2)</title>
          <description>In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium 18 µg (Continued Into Stage 2)</title>
          <description>Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Continued Into Stage 2)</title>
          <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="E5">
          <title>Indacaterol 75 µg (Not Continued Into Stage 2)</title>
          <description>In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="E6">
          <title>Indacaterol 600 µg (Not Continued Into Stage 2)</title>
          <description>In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
        <group group_id="E7">
          <title>Formoterol 12 µg (Not Continued Into Stage 2)</title>
          <description>In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Endocardial fibroelastosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Ear injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Glasgow coma scale abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Anaplastic large cell lymphoma T- and null-cell types</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Visual midline shift syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pelvic peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="155" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="44" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="416"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="416"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="418"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

